mirena
bayer ag - iud in plastica con progesterone - iud in plastica con progesterone
mirena intrauterines wirkstofffreisetzungssystem
bayer (schweiz) ag - levonorgestrelum - intrauterines wirkstofffreisetzungssystem - levonorgestrelum 52 mg cum liberatione 20 µg/24 h, poly(dimethylsiloxani) elastomerum, silica colloidalis anhydrica, polyethylenum, barii sulfas, e 172 (nigrum) pro praeparatione. - intrauterine kontrazeption / idiopathische hypermenorrhoe / schutz vor endometriumshyperplasie bei Östrogensubstitution - synthetika
lastan
so.se.pharm s.r.l. societa' di servizio per l'industria farmaceutica ed affini - losartan - losartan
comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren
pfizer ag - tozinameranum, riltozinameranum - comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren - suspension: tozinameranum 15 µg pro dosi, riltozinameranum 15 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro dosi. - comirnaty original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 18 jahren - vaccini
comirnaty
biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccini - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'uso di questo vaccino dovrebbe essere in conformità con le raccomandazioni ufficiali.
comirnaty 3 mikrogramm/dosis konzentrat zur herstellung einer injektionsdispersion comirnaty 3 mikrogramm/dosis konzentrat zur herstellung einer injektionsdispersion
pfizer ag - tozinameranum - comirnaty 3 mikrogramm/dosis konzentrat zur herstellung einer injektionsdispersion - suspension: tozinameranum 3 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro dosi. - vaccini
comirnaty konzentrat zur herstellung einer injektionsdispersion
pfizer ag - tozinameranum - konzentrat zur herstellung einer injektionsdispersion - tozinameranum 30 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas) pro dosi, 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum pro dosi, 1,2-distearoyl-sn-glycero-3-phosphocholinum pro dosi, cholesterolum pro dosi, saccharum pro dosi, natrii chloridum pro dosi, natrii hydroxidum, dinatrii phosphas dihydricus pro dosi, kalii dihydrogenophosphas pro dosi, kalii chloridum pro dosi, acidum hydrochloridum, aqua ad iniectabile, natrium 0.16 mg et kalium 0.01 mg pro dosi. - comirnaty ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 12 jahren - vaccini
comirnaty original/omicron ba. 4-5 0.225 mg injektionsdispersion
pfizer ag - tozinameranum, famtozinameranum - injektionsdispersion - suspension: tozinameranum 0.05 mg/ml, famtozinameranum 0.05 mg/ml, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, 1 ml corresp.. - comirnaty original/omicron ba.4-5 15/15 mikrogramm pro dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 12 jahren. - vaccini
comirnaty omicron xbb.1.5 (30 mikrogramm)/dosis injektionsdispersion
pfizer ag - raxtozinameranum - injektionsdispersion - suspension: raxtozinameranum 30 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, 1 ml corresp.. - comirnaty omicron xbb.1.5 (30 mikrogramm)/dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 12 jahren - vaccini
comirnaty® 30 mikrogramm/dosis gebrauchsfertige injektionsdispersion für personen ab 12 jahren
pfizer ag - tozinameranum - gebrauchsfertige injektionsdispersion für personen ab 12 jahren - suspension: tozinameranum 0.1 mg/ml, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro praeparatione. - vaccini